Targeting the structure of pancreatic tumors to improve treatment outcomes
Targeting tumor architecture as a novel therapeutic strategy for pancreatic cancer
This study is looking at new ways to treat pancreatic cancer by understanding how the tumor itself is built and how its cells work together, with the hope of finding better treatments for patients who often struggle with current options.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project ID | NIH-11030792 on NIH RePORTER |
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDAC), a type of cancer that is often resistant to chemotherapy. The project aims to explore new therapeutic strategies by targeting the unique architecture of tumors, specifically the properties of the tumor tissue itself. By understanding how different types of tumor glands behave and interact, the researchers hope to disrupt the tumor's ability to grow and resist treatment. This approach is innovative as it shifts the focus from the surrounding tissue to the tumor cells, potentially leading to more effective therapies for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have been diagnosed with pancreatic ductal adenocarcinoma.
Not a fit: Patients with other types of cancer or those who are not diagnosed with pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve outcomes for patients with pancreatic cancer.
How similar studies have performed: While targeting tumor architecture is a relatively novel approach, previous studies have shown promise in understanding tumor behavior and developing new therapies.
Where this research is happening
Dallas, United States
- Ut Southwestern Medical Center — Dallas, United States (Active)
Researchers
- Principal investigator: Ligorio, Matteo — Ut Southwestern Medical Center
- Study coordinator: Ligorio, Matteo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.